Clinical trial
Recombinant Human Erythropoietin Dose, Serum Adiponectin, and All-Cause Mortality in Patients Beginning Hemodialysis
NCT00457535 is registered in ClinicalTrials.gov with Hamamatsu University as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Recombinant Human Erythropoietin Dose, Serum Adiponectin, and All-Cause Mortality in Patients Beginning Hemodialysis
- Lead sponsor
- Hamamatsu University
- Phase
- Observational
- Overall status
- Terminated
- Start date
- August 31, 2000
- Completion date
- July 31, 2004
- Enrollment
- Not reported
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.
renal dialysis